Standard Chem & Pharm CO., LTD. Logo

Standard Chem & Pharm CO., LTD.

1720.TW

(2.8)
Stock Price

63,30 TWD

7.39% ROA

15.92% ROE

13.56x PER

Market Cap.

11.579.500.800,00 TWD

16.43% DER

4.17% Yield

12.92% NPM

Standard Chem & Pharm CO., LTD. Stock Analysis

Standard Chem & Pharm CO., LTD. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Standard Chem & Pharm CO., LTD. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (23.04%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 DER

The stock has a low debt to equity ratio (39%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

5 ROA

The stock's ROA (9.76%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 PBV

The stock's PBV ratio (2.32x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (462) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Standard Chem & Pharm CO., LTD. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Standard Chem & Pharm CO., LTD. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Standard Chem & Pharm CO., LTD. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Standard Chem & Pharm CO., LTD. Revenue
Year Revenue Growth
2006 1.924.414.000
2007 2.011.721.000 4.34%
2008 2.182.198.000 7.81%
2009 2.284.616.000 4.48%
2010 2.894.482.000 21.07%
2011 3.332.008.000 13.13%
2012 3.373.811.000 1.24%
2013 3.053.983.000 -10.47%
2014 3.295.656.000 7.33%
2015 3.321.366.000 0.77%
2016 3.673.801.000 9.59%
2017 3.848.684.000 4.54%
2018 3.573.093.000 -7.71%
2019 3.937.129.000 9.25%
2020 4.305.400.000 8.55%
2021 4.604.082.000 6.49%
2022 5.851.368.000 21.32%
2023 6.582.124.000 11.1%
2023 6.239.768.000 -5.49%
2024 7.040.416.000 11.37%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Standard Chem & Pharm CO., LTD. Research and Development Expenses
Year Research and Development Expenses Growth
2006 130.309.000
2007 149.574.000 12.88%
2008 148.623.000 -0.64%
2009 147.417.000 -0.82%
2010 137.940.000 -6.87%
2011 175.707.000 21.49%
2012 204.746.000 14.18%
2013 226.429.000 9.58%
2014 242.770.000 6.73%
2015 238.982.000 -1.59%
2016 241.116.000 0.89%
2017 239.633.000 -0.62%
2018 224.918.000 -6.54%
2019 225.765.000 0.38%
2020 227.211.000 0.64%
2021 241.788.000 6.03%
2022 251.878.000 4.01%
2023 286.044.000 11.94%
2023 266.272.000 -7.43%
2024 315.992.000 15.73%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Standard Chem & Pharm CO., LTD. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 112.142.000
2007 141.466.000 20.73%
2008 133.448.000 -6.01%
2009 133.914.000 0.35%
2010 221.910.000 39.65%
2011 237.640.000 6.62%
2012 263.324.000 9.75%
2013 295.311.000 10.83%
2014 288.219.000 -2.46%
2015 253.343.000 -13.77%
2016 275.828.000 8.15%
2017 324.675.000 15.04%
2018 295.427.000 -9.9%
2019 283.246.000 -4.3%
2020 283.997.000 0.26%
2021 272.547.000 -4.2%
2022 353.329.000 22.86%
2023 440.716.000 19.83%
2023 414.102.000 -6.43%
2024 483.836.000 14.41%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Standard Chem & Pharm CO., LTD. EBITDA
Year EBITDA Growth
2006 472.014.000
2007 429.136.000 -9.99%
2008 444.503.000 3.46%
2009 415.661.000 -6.94%
2010 471.488.000 11.84%
2011 470.889.000 -0.13%
2012 431.593.000 -9.1%
2013 519.770.000 16.96%
2014 617.509.000 15.83%
2015 632.825.000 2.42%
2016 656.980.000 3.68%
2017 749.878.000 12.39%
2018 734.929.000 -2.03%
2019 804.368.000 8.63%
2020 1.007.848.000 20.19%
2021 1.242.995.000 18.92%
2022 1.735.125.000 28.36%
2023 2.015.564.000 13.91%
2023 1.578.976.000 -27.65%
2024 1.895.476.000 16.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Standard Chem & Pharm CO., LTD. Gross Profit
Year Gross Profit Growth
2006 1.011.190.000
2007 1.027.549.000 1.59%
2008 1.063.002.000 3.34%
2009 1.049.179.000 -1.32%
2010 1.230.002.000 14.7%
2011 1.332.251.000 7.67%
2012 1.314.826.000 -1.33%
2013 1.297.598.000 -1.33%
2014 1.447.698.000 10.37%
2015 1.495.081.000 3.17%
2016 1.576.259.000 5.15%
2017 1.748.998.000 9.88%
2018 1.544.610.000 -13.23%
2019 1.709.131.000 9.63%
2020 1.919.838.000 10.98%
2021 2.067.873.000 7.16%
2022 2.487.613.000 16.87%
2023 2.821.488.000 11.83%
2023 2.725.378.000 -3.53%
2024 3.061.400.000 10.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Standard Chem & Pharm CO., LTD. Net Profit
Year Net Profit Growth
2006 323.443.000
2007 267.715.000 -20.82%
2008 274.597.000 2.51%
2009 293.463.000 6.43%
2010 210.053.000 -39.71%
2011 246.748.000 14.87%
2012 271.426.000 9.09%
2013 298.386.000 9.04%
2014 374.235.000 20.27%
2015 347.894.000 -7.57%
2016 340.216.000 -2.26%
2017 363.286.000 6.35%
2018 374.359.000 2.96%
2019 376.482.000 0.56%
2020 524.172.000 28.18%
2021 706.734.000 25.83%
2022 1.153.620.000 38.74%
2023 895.536.000 -28.82%
2023 834.886.000 -7.26%
2024 863.068.000 3.27%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Standard Chem & Pharm CO., LTD. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 2
2007 2 0%
2008 2 0%
2009 2 0%
2010 1 0%
2011 1 0%
2012 2 0%
2013 2 0%
2014 2 50%
2015 2 -100%
2016 2 0%
2017 2 50%
2018 2 0%
2019 2 0%
2020 3 0%
2021 4 33.33%
2022 6 50%
2023 5 -20%
2023 5 -25%
2024 5 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Standard Chem & Pharm CO., LTD. Free Cashflow
Year Free Cashflow Growth
2006 263.739.000
2007 250.880.000 -5.13%
2008 526.669.000 52.36%
2009 368.089.000 -43.08%
2010 -37.185.000 1089.89%
2011 106.993.000 134.75%
2012 155.485.000 31.19%
2013 4.532.000 -3330.83%
2014 404.777.000 98.88%
2015 471.884.000 14.22%
2016 127.453.000 -270.24%
2017 323.096.000 60.55%
2018 315.577.000 -2.38%
2019 458.830.000 31.22%
2020 570.093.000 19.52%
2021 609.118.000 6.41%
2022 30.292.000 -1910.82%
2023 200.286.000 84.88%
2023 710.827.000 71.82%
2024 74.115.000 -859.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Standard Chem & Pharm CO., LTD. Operating Cashflow
Year Operating Cashflow Growth
2006 358.745.000
2007 323.595.000 -10.86%
2008 719.169.000 55%
2009 634.227.000 -13.39%
2010 272.474.000 -132.77%
2011 405.494.000 32.8%
2012 402.246.000 -0.81%
2013 427.259.000 5.85%
2014 582.305.000 26.63%
2015 650.865.000 10.53%
2016 305.376.000 -113.14%
2017 708.738.000 56.91%
2018 484.935.000 -46.15%
2019 637.939.000 23.98%
2020 922.580.000 30.85%
2021 827.034.000 -11.55%
2022 1.227.834.000 32.64%
2023 364.761.000 -236.61%
2023 1.336.523.000 72.71%
2024 166.682.000 -701.84%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Standard Chem & Pharm CO., LTD. Capital Expenditure
Year Capital Expenditure Growth
2006 95.006.000
2007 72.715.000 -30.66%
2008 192.500.000 62.23%
2009 266.138.000 27.67%
2010 309.659.000 14.05%
2011 298.501.000 -3.74%
2012 246.761.000 -20.97%
2013 422.727.000 41.63%
2014 177.528.000 -138.12%
2015 178.981.000 0.81%
2016 177.923.000 -0.59%
2017 385.642.000 53.86%
2018 169.358.000 -127.71%
2019 179.109.000 5.44%
2020 352.487.000 49.19%
2021 217.916.000 -61.75%
2022 1.197.542.000 81.8%
2023 164.475.000 -628.1%
2023 625.696.000 73.71%
2024 92.567.000 -575.94%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Standard Chem & Pharm CO., LTD. Equity
Year Equity Growth
2006 2.576.219.000
2007 2.578.420.000 0.09%
2008 2.604.789.000 1.01%
2009 2.809.088.000 7.27%
2010 2.914.146.000 3.61%
2011 3.121.909.000 6.65%
2012 3.306.357.000 5.58%
2013 3.582.457.000 7.71%
2014 3.605.752.000 0.65%
2015 3.886.921.000 7.23%
2016 4.196.664.000 7.38%
2017 4.202.185.000 0.13%
2018 4.246.312.000 1.04%
2019 4.646.421.000 8.61%
2020 4.905.835.000 5.29%
2021 6.799.614.000 27.85%
2022 7.435.601.000 8.55%
2023 7.826.714.000 5%
2023 8.137.337.000 3.82%
2024 8.674.287.000 6.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Standard Chem & Pharm CO., LTD. Assets
Year Assets Growth
2006 3.488.070.000
2007 3.305.084.000 -5.54%
2008 3.548.261.000 6.85%
2009 3.844.155.000 7.7%
2010 4.519.546.000 14.94%
2011 4.866.120.000 7.12%
2012 5.123.310.000 5.02%
2013 5.353.193.000 4.29%
2014 5.374.647.000 0.4%
2015 5.795.287.000 7.26%
2016 6.225.840.000 6.92%
2017 6.374.217.000 2.33%
2018 6.439.113.000 1.01%
2019 6.928.004.000 7.06%
2020 7.049.447.000 1.72%
2021 10.104.021.000 30.23%
2022 10.968.259.000 7.88%
2023 10.953.524.000 -0.13%
2023 11.188.724.000 2.1%
2024 11.769.640.000 4.94%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Standard Chem & Pharm CO., LTD. Liabilities
Year Liabilities Growth
2006 911.851.000
2007 726.664.000 -25.48%
2008 943.472.000 22.98%
2009 1.035.067.000 8.85%
2010 1.605.400.000 35.53%
2011 1.744.211.000 7.96%
2012 1.816.953.000 4%
2013 1.770.736.000 -2.61%
2014 1.768.895.000 -0.1%
2015 1.908.366.000 7.31%
2016 2.029.176.000 5.95%
2017 2.172.032.000 6.58%
2018 2.192.801.000 0.95%
2019 2.281.583.000 3.89%
2020 2.143.612.000 -6.44%
2021 3.304.407.000 35.13%
2022 3.532.658.000 6.46%
2023 3.126.810.000 -12.98%
2023 3.051.387.000 -2.47%
2024 3.095.353.000 1.42%

Standard Chem & Pharm CO., LTD. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
37
Net Income per Share
4.78
Price to Earning Ratio
13.56x
Price To Sales Ratio
1.75x
POCF Ratio
9.62
PFCF Ratio
18.67
Price to Book Ratio
1.99
EV to Sales
1.68
EV Over EBITDA
5.83
EV to Operating CashFlow
9.25
EV to FreeCashFlow
17.95
Earnings Yield
0.07
FreeCashFlow Yield
0.05
Market Cap
11,58 Bil.
Enterprise Value
11,13 Bil.
Graham Number
59.18
Graham NetNet
4.8

Income Statement Metrics

Net Income per Share
4.78
Income Quality
0.99
ROE
0.16
Return On Assets
0.07
Return On Capital Employed
0.16
Net Income per EBT
0.57
EBT Per Ebit
0.99
Ebit per Revenue
0.23
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.07
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.43
Operating Profit Margin
0.23
Pretax Profit Margin
0.23
Net Profit Margin
0.13

Dividends

Dividend Yield
0.04
Dividend Yield %
4.17
Payout Ratio
0.52
Dividend Per Share
2.7

Operating Metrics

Operating Cashflow per Share
6.74
Free CashFlow per Share
3.47
Capex to Operating CashFlow
0.48
Capex to Revenue
0.09
Capex to Depreciation
1.53
Return on Invested Capital
0.18
Return on Tangible Assets
0.07
Days Sales Outstanding
92.2
Days Payables Outstanding
24.05
Days of Inventory on Hand
162.25
Receivables Turnover
3.96
Payables Turnover
15.18
Inventory Turnover
2.25
Capex per Share
3.27

Balance Sheet

Cash per Share
10,44
Book Value per Share
48,54
Tangible Book Value per Share
47.37
Shareholders Equity per Share
32.57
Interest Debt per Share
5.47
Debt to Equity
0.16
Debt to Assets
0.08
Net Debt to EBITDA
-0.23
Current Ratio
2.16
Tangible Asset Value
8,46 Bil.
Net Current Asset Value
2,25 Bil.
Invested Capital
7525318000
Working Capital
2,87 Bil.
Intangibles to Total Assets
0.02
Average Receivables
1,66 Bil.
Average Payables
0,26 Bil.
Average Inventory
1671637500
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Standard Chem & Pharm CO., LTD. Dividends
Year Dividends Growth
2000 0
2001 0 0%
2002 1 0%
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 100%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 100%
2013 1 0%
2014 3 50%
2015 1 -100%
2016 1 0%
2017 1 100%
2018 2 0%
2019 2 0%
2020 2 0%
2021 2 0%
2022 3 50%
2023 3 0%
2024 3 0%

Standard Chem & Pharm CO., LTD. Profile

About Standard Chem & Pharm CO., LTD.

Standard Chem & Pharm CO., LTD. engages in the manufacture and sale of pharmaceutical products, supplements, and APIs in Taiwan. It offers various pharmaceutical products, including circulatory system, digestive system, respiratory system, antihistamine, C.N.S, metabolism, anti-microbial, and skin and mucous membrane drugs, as well as human and veterinary APIs, and excipients. The company was founded in 1967 and is headquartered in Tainan City, Taiwan.

CEO
Mr. Tzu-Ting Fan
Employee
1.130
Address
No. 6-20, Tuku
Tainan City, 73055

Standard Chem & Pharm CO., LTD. Executives & BODs

Standard Chem & Pharm CO., LTD. Executives & BODs
# Name Age
1 Mr. Tzu-Ting Fan
Chairman of the Board, President & GM
70
2 Chin Wen Chang
Financial Officer, Accounting Officer & Corporate Governance Officer
70
3 Mr. Chin-Tsai Fan
GM & Director
70

Standard Chem & Pharm CO., LTD. Competitors